Puma Biotechnology director sells 5K shares at $9.10

A PUMA Biotechnology director reported a small Rule 10b5-1 trading-plan sale and continues to hold a meaningful direct and family position in PBYI shares.

Available on EDGAR 09/16/2026 - 09:14 PM EDT Accepted by SEC EDGAR 09/16/2026 - 09:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

PUMA BIOTECHNOLOGY, INC. (PBYI) director Troy Edward Wilson reported selling 5,000 shares of Common Stock on September 14, 2026 at $9.10 per share in an open-market or private transaction made under a Rule 10b5-1(c) trading plan adopted on June 15, 2026. Following this sale, he holds 54,750 shares directly and additional indirect holdings of 400 shares for one child and 150 shares for another child.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider WILSON TROY EDWARD

Role Director

Sold 5,000 shs ($46K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,000	$9.10	$46K
Holding	Common Stock	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 54,750 shares (Direct); Common Stock — 400 shares (Indirect, By Child #1); Common Stock — 150 shares (Indirect, By Child #2)

Footnotes (1)

1. F1. Adoption date of referenced 10b5-1(c) plan is: 06-15-2026

Key Figures

Shares sold: 5,000 shares of Common Stock Sale price per share: $9.10 per share Sale transaction value: $45,500 +5 more

8 metrics

Shares sold 5,000 shares of Common Stock Sale reported for September 14, 2026

Sale price per share $9.10 per share Common Stock sale on September 14, 2026

Sale transaction value $45,500 5,000 shares sold at $9.10 per share

Direct holdings after transaction 54,750 shares Common Stock held directly after September 14, 2026 sale

Indirect holdings by Child #1 400 shares Common Stock reported as indirectly held for Child #1

Indirect holdings by Child #2 150 shares Common Stock reported as indirectly held for Child #2

Net shares sold 5,000 shares Net share change across reported non-derivative transactions in this Form 4

Rule 10b5-1(c) plan adoption date June 15, 2026 Adoption date of trading plan referenced in the sale footnote

Key Terms

10b5-1(c) plan

1 terms

10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 06-15-2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PBYI director Troy Edward Wilson report?

He reported a sale of 5,000 shares of Common Stock on September 14, 2026, executed as an open-market or private transaction under a Rule 10b5-1(c) trading plan.

At what price were the PBYI shares sold by the director?

The 5,000 PBYI shares were sold at $9.10 per share on September 14, 2026, as reported for the Common Stock transaction.

How many PBYI shares does Troy Edward Wilson hold after this transaction?

After the reported sale, he holds 54,750 shares directly of PUMA Biotechnology Common Stock, plus indirect holdings of 400 shares for one child and 150 shares for another child.

Was the PBYI insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sale was made under a Rule 10b5-1(c) trading plan with an adoption date of June 15, 2026.

What is the total value of the PBYI shares sold in this transaction?

Based on 5,000 shares sold at $9.10 per share, the reported transaction represents total consideration of $45,500.

Does the director report any derivative securities of PBYI in this Form 4?

No. The Form 4 reports no derivative securities transactions; it lists one sale of Common Stock and the resulting direct and indirect share holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		S(1)		5,000	D	$9.1	54,750	D
Common Stock								400	I	By Child #1
Common Stock								150	I	By Child #2

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Adoption date of referenced 10b5-1(c) plan is: 06-15-2026

	/s/ Chirs Culotta as attorney-in-fact for Troy E. Wilson	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)